top of page
CGTI.png

Jesse McCool

CSO of Bionova Scientific

Jesse is a seasoned leader in the biopharmaceutical development field with over two decades of experience at companies like Lonza, Cytovance Biologics, Mascoma, Clean Harbors, and Wheeler Bio. With a robust background spanning both private and public enterprises, he has successfully navigated P&L responsibilities and client-facing roles while showcasing versatile leadership across multiple domains including innovation, development, manufacturing, supply chain, quality assurance, regulatory affairs, finance, and commercial operations. During his tenure as Chief Technology Officer at Cytovance Biologics in Oklahoma City, Jesse played a crucial role in driving remarkable growth, tripling the company's top-line revenue over five years and significantly boosting EBITDA by expanding commercial manufacturing capabilities. His leadership as CEO was instrumental in guiding Cytovance through a successful IPO in 2020, raising $585 million USD for the parent company. Following his impactful seven-year journey at Cytovance, Jesse ventured into entrepreneurial endeavors as an entrepreneur-in-residence at Echo Investment Capital. Here, he co-founded Wheeler Bio in 2021, focusing on clinical-scale manufacturing, a testament to his commitment to advancing the industry. Jesse is a scientist by training, holding a Ph.D. in Microbiology from the University of Massachusetts, complemented by postdoctoral work at Dartmouth. His work in academia includes making contributions to over 25 peer-reviewed journal articles and book chapters, alongside being a sought-after presenter at industry conferences. Despite being a New England native, Jesse has made Oklahoma his home since 2013, where he resides with his family.

Share
  • LinkedIn
  • Youtube
  • X
  • Instagram
How we drive innovation
STORIES
MEETINGS
MEMBERS
Speakers

Uwe Gottschalk

Uwe Gottschalk is Chief Scientific Officer (CSO) at Lonza since July 2017. Between 2014 and 2017 he served as a Chief Technology Officer where he established and led the global Research and Technology organisation of Lonza Pharma/Biotech.

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Thomas Potgieter

SVP of Global Cell Therapy Development & Operations at Bristol Myers Squibb

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Angela Vollstedt, PhD MBA

Director Global Cell & Gene Therapies Portfolio Management at Novartis

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Paolo Martini

Chief Research & Development Officer at ReAlta Life Sciences former CSO at Moderna

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Gwendolyn Binder PhD

President, Science and Technology at Cabaletta Bio

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Warner Biddle

CEO at Kyverna Therapeutics former interim CEO at Kite a Gilead Company

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS
bottom of page